VYNE NASDAQ
VYNE Therapeutics Inc.
1W: -28.6%
1M: +4282.4%
3M: +4327.2%
YTD: +4825.0%
1Y: +2031.3%
3Y: +556.5%
5Y: -42.3%
$28.56
Last traded 2026-07-27 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-08-12
Earliest Filing
2026-01-30
Latest Filing
partner: 5
target: 3
acquirer: 1
investor: 1
Counterparties (Filed by VYNE)
10 relationshipsCompanies named in VYNE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Yarrow Bioscience, Inc. | — | target | Target company in the merger agreement with VYNE Therapeutics Inc. | 2026-01-30 | View |
| Yarrow Merger Sub Corp. | — | target | Wholly-owned subsidiary of VYNE Therapeutics Inc. and party to the merger agreement. | 2026-01-30 | View |
| Yarrow Bioscience, Inc. | — | target | Target company in a merger agreement with VYNE Therapeutics Inc. | 2025-12-17 | View |
| Yellow Merger Sub Corp. | — | acquirer | Wholly owned subsidiary of VYNE Therapeutics Inc. entering merger with Yarrow Bioscience, Inc. | 2025-12-17 | View |
| Tay Therapeutics Limited | — | partner | Entered into a License Agreement granting VYNE Therapeutics Inc. an exclusive license to exploit certain BET inhibitors. | 2023-05-01 | View |
| Tay Therapeutics Limited | — | partner | Extended option agreement for exclusive worldwide rights to research, develop and commercialize Oral BETi Compounds. | 2023-02-28 | View |
| In4Derm Limited | — | partner | Exclusive option agreement for Oral BETi Compounds rights | 2022-06-17 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Entered into a purchase agreement to buy up to $30,000,000 of VYNE Therapeutics Inc. common stock over a 36-month term. | 2022-03-15 | View |
| Cantor Fitzgerald & Co. | — | partner | Sales agent for the Controlled Equity Offering | 2021-08-12 | View |
| In4Derm Limited | — | partner | Partner in exclusive option and license agreement for BETi compounds for topical and oral formulations. | 2021-08-12 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-30 | Other Events | View | |
| 2026-07-28 | Material Agreement; Acquisition/Disposition; Earnings Release; Unregistered Equity Sales; Change in | Agreement Acquisition | View |
| 2026-07-21 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-20 | Shareholder Vote | View | |
| 2026-07-14 | Regulation FD; Exhibits | View | |
| 2026-07-10 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-21 | Regulation FD; Exhibits | View | |
| 2026-03-11 | Notice of Delisting or Transfer | View | |
| 2026-01-30 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-12-17 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Changes in Contro | Agreement | View |
| 2025-12-12 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-12 | Notice of Delisting or Transfer | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-07-30 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Other Events; Financial Statements and Exhibits | View | |
| 2024-12-23 | Other Events; Financial Statements and Exhibits | View | |
| 2024-12-12 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR